Sirolimus in renal transplant recipients with malignancies in Germany

BACKGROUND: Renal transplant recipients have an increased cancer risk. The mammalian target of rapamycin inhibitor sirolimus (SRL) has immunosuppressive and antitumour activities but knowledge about its use in recipients with cancer is limited. METHODS: We retrospectively analysed 726 renal allograf...

Descripción completa

Detalles Bibliográficos
Autores principales: Naik, Marcel G, Arns, Wolfgang, Budde, Klemens, Diekmann, Fritz, Eitner, Frank, Gwinner, Wilfried, Heyne, Nils, Jürgensen, Jan Steffen, Morath, Christian, Riester, Udo, Heller, Katharina M, Fischereder, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8406058/
https://www.ncbi.nlm.nih.gov/pubmed/34476091
http://dx.doi.org/10.1093/ckj/sfaa262

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8406058/
https://www.ncbi.nlm.nih.gov/pubmed/34476091
http://dx.doi.org/10.1093/ckj/sfaa262

Ejemplares similares